Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT
: Donal P. McLornan, Richard Szydlo, Marie Robin, Anja van Biezen, Linda Koster, Henrik J. P. Blok, Maria T. Van Lint, Jürgen Finke, Antonin Vitek, Kristina Carlson, Laimonas Griskevicius, Ernst Holler, Maija Itälä-Remes, Michel Schaap, Gerard Socié, Jacques-Olivier Bay, Yves Beguin, Benedetto Bruno, Jan J. Cornelissen, Tobias Gedde-Dahl, Per Ljungman, Marie T. Rubio, Ibrahim Yakoub-Agha, Evgeny Klyuchnikov, Eduardo Olavarria, Yves Chalandon, Nicolaus Kröger
Publisher: WILEY
: 2018
: British Journal of Haematology
: BRITISH JOURNAL OF HAEMATOLOGY
: BRIT J HAEMATOL
: 182
: 3
: 418
: 422
: 5
: 0007-1048
: 1365-2141
DOI: https://doi.org/10.1111/bjh.15407
Allogeneic Haematopoietic Stem Cell Transplant (allo-HSCT) remains the only curative approach for Myelofibrosis (MF). Scarce information exists in the literature on the outcome and, indeed, management of those MF patients who relapse following transplant. We hereby report on the management and outcome of 202 patients who relapsed post allo-HSCT for MF.
